# Drug of interest
My drug of interest is lumefantrine.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. CYP3A4 (z: 37.5)
2. ABCC2 (z: 35.71)
3. CYP3A5 (z: 26.31)
4. ZSCAN25 (z: 15.83)
5. CYP2D6 (z: 5.91)
6. CYP3A43 (z: 2.76)
7. CYP3A7 (z: 2.76)
8. CYP2D7 (z: 2.23)
9. ZNF789 (z: 2.12)
10. ZNF165 (z: 1.05)
11. CYP2S1 (z: 0.93)
12. ABCB1 (z: 0.91)
13. ZNF565 (z: 0.87)
14. ZNF211 (z: 0.79)
15. ZNF568 (z: 0.76)
16. FMO5 (z: 0.56)
17. CYP2C19 (z: 0.52)
18. ZNF697 (z: 0.51)
19. FMO4 (z: 0.49)
20. CYP2A13 (z: 0.47)
21. ZNF432 (z: 0.47)
22. CYP2C18 (z: 0.43)
23. ZNF100 (z: 0.37)
24. CYP2F1 (z: 0.36)
25. ZNF613 (z: 0.36)
26. CYP2C9 (z: 0.34)
27. CYP26C1 (z: 0.31)
28. CYP4F11 (z: 0.3)
29. ABCB4 (z: 0.3)
30. OTC (z: 0.29)
31. CYP4B1 (z: 0.28)
32. CYP2E1 (z: 0.27)
33. CYP2A7 (z: 0.26)
34. ZNF816 (z: 0.22)
35. CYP4F8 (z: 0.22)
36. PSORS1C2 (z: 0.22)
37. CYP4F12 (z: 0.22)
38. CYP4F2 (z: 0.21)
39. CYP2J2 (z: 0.19)
40. C6orf15 (z: 0.18)
41. PLGLB1 (z: 0.18)
42. ABCG2 (z: 0.15)
43. DDX39B (z: 0.15)
44. PSORS1C1 (z: 0.15)
45. CYP8B1 (z: 0.14)
46. CYP4A11 (z: 0.14)
47. PPP1R18 (z: 0.14)
48. RBFOX1 (z: 0.13)
49. HSPA1A (z: 0.13)
50. CYP2C8 (z: 0.13)

# Known pharmacogenetic associations
In addition, please consider that the following pharmacogenetic interactions are already known for this drug, according to PharmGKB:
- CYP3A4
- ABCC2
- CYP3A5
- ZSCAN25

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**lumefantrine**: Variants in the CYP3A4 gene significantly affect the metabolism of lumefantrine, altering drug levels and impacting its efficacy and safety, while the role of CYP2D6 is secondary but still contributes to variability in treatment outcomes. These pharmacokinetic gene interactions are crucial for personalizing malaria treatment regimens based on individual genetic profiles.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**CYP3A4**: CYP3A4, significantly expressed in the liver and small intestine, influences the metabolism and thus the effects and toxicity of many drugs, including tacrolimus, statins like atorvastatin and lovastatin, chemotherapeutics such as docetaxel, and sedatives like midazolam. Interaction with inducers or inhibitors like carbamazepine and erythromycin respectively can either increase or decrease CYP3A4's activity, affecting the metabolism of other drugs such as sildenafil and necessitating dosage adjustments due to changes in pharmacokinetic profiles.

**ABCC2**: ABCC2 gene variants influence the function of the MRP2 protein, affecting the pharmacokinetics and therapeutic outcomes of various drugs. For example, genetic variations like c.1249G>A and c.3972C>T can alter the excretion and plasma concentrations of drugs such as methotrexate, mycophenolate mofetil, tacrolimus, rosuvastatin, and others including irinotecan and docetaxel, thereby impacting drug effectiveness and toxicity. Non-pharmacokinetic interactions involve drugs like clopidogrel and sorafenib, which may affect therapeutic outcomes through MRP2-related pathways.

**CYP3A5**: CYP3A5 plays a key role in the metabolism of several drugs, including immunosuppressants like tacrolimus and cyclosporine, where genetic variants impact dosing due to altered metabolism rates. This enzyme also affects the metabolism and effectiveness of other drugs such as itraconazole, statins (simvastatin and atorvastatin), apixaban, vincristine, ondansetron, atazanavir, and fentanyl, which in turn influences their therapeutic outcomes and risk profiles.

**ZSCAN25**: ZSCAN25 is hypothesized to interact with a diverse range of drugs including apixaban, finasteride, and simvastatin, among others, due to its role in transcriptional regulation which could impact pharmacodynamic processes. However, there is currently no direct evidence or mechanistic insights linking ZSCAN25 to specific pharmacodynamic or pharmacokinetic changes with these medications, making any such interactions speculative at this point.

**CYP2D6**: CYP2D6 enzyme is crucial in metabolizing drugs, including codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol, with genetic variations influencing their plasma levels and effects. Differences in CYP2D6 activity can lead to different therapeutic outcomes, with poor metabolizers experiencing potential toxicity and ultrarapid metabolizers having reduced drug efficacy, making pharmacogenetic knowledge essential for adjusting dosages or choosing alternative therapies to optimize treatment efficacy and safety.

**CYP3A43**: The gene CYP3A43, although not a major player in drug metabolism compared to other enzymes in its subfamily, is known to have specific pharmacokinetic interactions with drugs like olanzapine and ticagrelor, influencing their clearance and plasma concentrations to a minor degree. Its interactions with other antipsychotic drugs such as quetiapine, haloperidol, aripiprazole, risperidone, and clozapine are less defined and are likely related to broader metabolic pathways or pharmacodynamic responses, where CYP3A43 plays a marginal role.

**CYP3A7**: The CYP3A7 enzyme, important in fetal liver metabolism, interacts with drugs like atorvastatin and tacrolimus by potentially altering their pharmacokinetic profiles and systemic exposure during fetal development due to its activity in metabolizing these CYP3A substrates. Additionally, corticosteroids such as betamethasone and cortisone acetate may also interact with CYP3A7, affecting their metabolic rates and therapeutic outcomes in neonates and infants, though the specific pathway (pharmacokinetic or pharmacodynamic) of these interactions is less defined.

**CYP2D7**: CYP2D7, a pseudogene, does not encode a functional enzyme and thus does not partake in the metabolism of drugs, unlike its close relative CYP2D6, which metabolizes about 25% of clinically used drugs such as antidepressants, antipsychotics, beta-blockers, and opioids. Although CYP2D7 does not directly interact with these drugs, its similarity to CYP2D6 makes its study important for ensuring accurate pharmacogenetic testing and understanding genetic misannotations which can affect drug dosing and therapy.

**ZNF789**: Although there is no direct evidence linking the ZNF789 gene to the pharmacokinetics or pharmacodynamics of the immunosuppressant drug tacrolimus, ZNF789's role in regulating gene expression suggests it could indirectly affect tacrolimus's effectiveness and toxicity by potentially influencing the expression of genes involved in the drug's metabolism or action. This interaction likely occurs through a cascade of gene expression modulations rather than through direct handling of the drug.

**ZNF165**: ZNF165, or Zinc Finger Protein 165, has not been directly implicated in pharmacogenetic interactions with any contemporary pharmaceuticals and does not affect the pharmacokinetics or pharmacodynamics of therapeutic substances. Although it might have potential indirect effects on drug efficacy or toxicity in the future, particularly in therapies related to reproductive health or cancer, there is currently no evidence linking it to specific drug interactions.

**CYP2S1**: CYP2S1, a cytochrome P450 enzyme, influences the metabolism and efficacy of drugs, especially those administered via inhalation or topically, due to its expression in the liver, lungs, and skin. Although specific drugs affected by CYP2S1 are not well-determined, variations in the CYP2S1 gene can alter how these drugs are metabolized, potentially affecting their efficacy and toxicity.

**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**ZNF565**: The drug methylphenidate, used for ADHD, is metabolized primarily by liver enzymes such as CYP2D6, and while not well-documented, there is speculation that ZNF565 could affect its metabolism through its role in regulating the expression of genes for these enzymes. This interaction, however, remains speculative without direct evidence showing ZNF565â€™s influence on these pathways.

**ZNF211**: While there are no directly documented pharmacogenetic interactions between the gene ZNF211 and the ADHD medication methylphenidate, the gene's role in regulating neuronal gene expression might hypothetically affect the drug's effectiveness or patient responsiveness through pharmacodynamic mechanisms. This speculative association is based on ZNF211's function in transcriptional regulation impacting neuronal circuits or neurotransmitter systems influenced by methylphenidate, but concrete evidence is presently lacking.

**ZNF568**: Variations in the ZNF568 gene, involved in transcriptional regulation, might indirectly affect the efficacy and safety of drugs by influencing the expression patterns of genes tied to drug metabolism, transport, or action. Currently, no specific drugs have been conclusively identified to interact with ZNF568, and the gene's role in pharmacogenetics is primarily hypothetical.

**FMO5**: The FMO5 gene, unlike its family members, has a unique role in pharmacogenetics, particularly due to its broad substrate specificity and presence in the liver and small intestine. It indirectly influences drug metabolism, such as with metformin, by potentially altering the metabolic environment or modifying intermediate biomolecules, thus affecting the drug's efficacy and safety through non-traditional pathways related to its handling of metabolic byproducts connected to sulfur and nitrogen.

**CYP2C19**: The enzyme CYP2C19 significantly influences the metabolism of various drugs including clopidogrel, proton pump inhibitors (omeprazole, esomeprazole), antidepressants (citalopram, escitalopram), antiepileptics (phenytoin), antifungals (voriconazole), and analgesics (methadone, oxycodone), which impacts their therapeutic efficacy and safety. Variations in the CYP2C19 gene affect drug activation and metabolism, leading to different pharmacological outcomes and necessitating genotype-guided dosing to optimize treatment efficacy and minimize adverse effects.

**ZNF697**: As of now, there are no established pharmacogenetic interactions between the ZNF697 gene and any specific drugs. While ZNF697, a zinc finger protein implicated in DNA binding and transcription regulation, may theoretically affect drug actions indirectly through gene expression modulation or altering physiological states, any direct links to drug metabolism, efficacy, or toxicity are currently speculative and unconfirmed.

**FMO4**: The FMO4 gene encodes for the enzyme flavin-containing monooxygenase 4, which potentially contributes to the metabolism of drugs by affecting their pharmacokinetics, altering plasma drug levels, and impacting therapeutic outcomes or side effects. The exact drugs impacted by FMO4 are still speculative, as FMO4â€™s interactions with specific drugs are currently not well-documented and remain under research.

**CYP2A13**: CYP2A13, a cytochrome P450 enzyme primarily found in the respiratory tract, plays a significant role in activating procarcinogens in tobacco smoke, such as nitrosamines, impacting lung cancer risk among smokers. Although it does not metabolize nicotine directly, CYP2A13 affects the activation of other smoke components that interact with nicotine's pathway, potentially influencing nicotine addiction and cancer risks, with genetic variations in CYP2A13 altering susceptibility to these effects.

**ZNF432**: ZNF432, part of the zinc finger protein family, does not have clearly established pharmacogenetic interactions with specific drugs but is speculated to potentially influence the transcriptional responses to respiratory medications like salbutamol, budesonide, beclomethasone, and fluticasone propionate. Although these drugs work through anti-inflammatory and bronchodilatory effects, the role of ZNF432 could theoretically affect how cells manage inflammation and airway cell repair and apoptosis, though direct evidence of such interactions remains undocumented.

**CYP2C18**: CYP2C18 plays a modest role in the metabolism of drugs like warfarin, escitalopram, and clozapine, mainly affecting their clearance or efficacy to a lesser extent than more prominent CYP enzymes. Genetic variations in CYP2C18 could influence the pharmacodynamics of drugs such as clopidogrel and acenocoumarol, rather than their pharmacokinetic profiles, indicating a potential need for personalized medicine considerations despite the enzyme's relative minor role.

**ZNF100**: ZNF100, a zinc finger protein involved in transcriptional regulation, currently does not have established pharmacogenetic interactions with specific drugs, despite its potential role in gene expression and regulation which could impact drug efficacy and safety. No direct evidence links ZNF100's function with the pharmacokinetics or pharmacodynamics of specific medications, and it has not been identified in known disease pathways or drug responses in clinical settings.

**CYP2F1**: CYP2F1, involved mainly in metabolizing inhaled environmental pollutants like naphthalene, has limited direct interaction with common drugs but plays a role in the metabolism of certain pharmaceuticals such as imatinib due to shared metabolic pathways or competitive inhibition. Although CYP2F1 does not typically directly influence imatinib's metabolism, its interaction with similar chemical structures could alter the drug's efficacy or toxicity in individuals with specific gene variants.

**ZNF613**: Despite a lack of direct evidence linking ZNF613, a gene involved in DNA-binding and gene regulation, to pharmacokinetic or pharmacodynamic interactions, it is speculated that it could affect the efficacy of tamoxifen, anastrozole, and letrozole. These drugs, used in treating hormone-responsive breast cancer, primarily work by inhibiting the aromatase enzyme to reduce estrogen levels, and potential interactions with ZNF613 might involve regulatory controls related to estrogen receptor functions or gene expressions associated with estrogen.

**CYP2C9**: CYP2C9 gene polymorphisms influence the metabolism of various drugs, affecting their therapeutic effectiveness and risk of side effects. Drugs such as warfarin, phenytoin, celecoxib, losartan, and tolbutamide require dose customization based on CYP2C9 genetic variants to optimize treatment outcomes and minimize complications like bleeding, drug toxicity, and gastrointestinal issues.

**CYP26C1**: CYP26C1, responsible for retinoic acid metabolism, affects the pharmacokinetics of retinoids like isotretinoin and acitretin, where its genetic variations can alter drug metabolism, influencing their efficacy and safety. Increased CYP26C1 activity might reduce the effectiveness of these drugs by speeding up their metabolism, while decreased activity could increase drug toxicity by allowing higher drug concentrations in the body, suggesting a need for personalized dosing based on CYP26C1 genotype.

**CYP4F11**: The enzyme CYP4F11 is involved in the metabolism of drugs such as warfarin, aspirin, and erlotinib, influencing their effectiveness and safety by altering degradation rates, plasma levels, therapeutic efficacy, and the profile of side effects. Variations in the activity of CYP4F11 can affect how these drugs are processed in the body, thereby potentially impacting dosage requirements and risk of adverse effects.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drugâ€™s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**OTC**: Sodium phenylbutyrate and glycerol phenylbutyrate help in the treatment of OTC deficiency by promoting the excretion of nitrogen waste through alternative pathways, while their effectiveness can vary based on the specific mutations in the OTC gene affecting residual enzymatic activity. In contrast, valproic acid can worsen hyperammonemia in OTC deficiency patients by inhibiting key functions in the urea cycle, highlighting the necessity of adjusting its use depending on the patientâ€™s genetic profile.

**CYP4B1**: CYP4B1, which is involved in the metabolism of fatty acids and xenobiotics, may potentially interact with drugs like docetaxel and thalidomide due to their structural similarities to fatty acids. This interaction could alter the pharmacokinetics of these drugs, affecting their efficacy and safety, although direct evidence of this is currently limited.

**CYP2E1**: The gene CYP2E1 significantly impacts the metabolism of various drugs; for instance, in the case of acetaminophen and isoniazid, variations in CYP2E1 activity can lead to differences in the rate at which these drugs are metabolized, thereby affecting their efficacy, toxicity, and risk of adverse effects such as hepatotoxicity. Additionally, CYP2E1 metabolizes other substances like caffeine, theophylline, nicotine, and some procarcinogens, indicating that genetic variations could influence both therapeutic outcomes and disease risk through pharmacokinetic and possibly pharmacodynamic interactions.

**CYP2A7**: CYP2A7, a lesser-known member of the cytochrome P450 family, does not have well-established pharmacogenetic interactions with drugs like mercaptopurine, although it might theoretically affect mercaptopurine's metabolism similarly to its related isoform, CYP2A6. The interaction and impact of CYP2A7 on the metabolism of mercaptopurine are speculative and require further evidence, as mercaptopurine is primarily metabolized through other pathways involving TPMT and XO.

**ZNF816**: ZNF816, or Zinc Finger Protein 816, does not currently have a defined pharmacogenetic interaction with specific drugs but is involved in DNA-binding that could theoretically impact drug responses and disease mechanisms related to genomic stability and transcription dysregulation. However, any potential effect of ZNF816 on drug metabolism, efficacy, or toxicity remains speculative without direct evidence of its involvement in pharmacokinetics or pharmacodynamics.

**CYP4F8**: CYP4F8 plays a role in the metabolism of fatty acids and leukotriene B4, suggesting that variations in this gene could influence the metabolism and efficacy of dermatological and anti-inflammatory drugs, particularly those like montelukast or zileuton that target leukotriene pathways. The interaction of CYP4F8 with these drugs primarily affects their pharmacokinetics, potentially altering drug effectiveness and safety.

**PSORS1C2**: PSORS1C2, a gene associated with psoriasis susceptibility, may subtly affect the response to treatments like allopurinol, which is used for its anti-inflammatory effects in psoriasis, despite no direct pharmacokinetic interaction. Variants in PSORS1C2 could potentially influence the efficacy and safety of psoriasis therapies, particularly those targeting immune pathways, such as biologics and systemic medications.

**CYP4F12**: CYP4F12, a cytochrome P450 enzyme, influences the metabolism of drugs that interact with lipid metabolism pathways, including NSAIDs, by affecting processes like hydroxylation of fatty acids. Variants in CYP4F12 could alter the pharmacokinetics of these drugs, potentially impacting their efficacy and safety.

**CYP4F2**: CYP4F2 significantly influences the metabolism of drugs such as vitamin E, vitamin K1, warfarin, and acenocoumarol, affecting their bioavailability and dosing requirements. The enzyme's activity, particularly influenced by the V433M genetic variant, is crucial for the proper breakdown and clearance of these drugs, directly impacting their therapeutic levels and the potential for adverse effects.

**CYP2J2**: CYP2J2, primarily involved in metabolizing polyunsaturated fatty acids affecting cardiovascular physiology, does not have well-documented direct pharmacokinetic interactions with drugs like mycophenolate mofetil and tacrolimus. However, its role in modulating vascular tone and inflammation could potentially influence the pharmacodynamics of these immunosuppressive drugs used in organ transplantation and autoimmune diseases, despite the lack of a direct metabolic pathway involving CYP2J2.

**C6orf15**: C6orf15, a gene with suspected enzymatic activity and expression in immune-related tissues, may impact the pharmacodynamics of chemotherapy drugs like carboplatin and gemcitabine, potentially affecting their efficacy and toxicity due to its role in immune modulation. The exact pharmacogenetic interactions remain speculative without concrete data, though the gene's link to immune responses suggests possible relevance in the context of cancer treatment.

**PLGLB1**: Although the PLGLB1 gene is structurally similar to plasminogen and is involved in the fibrinolytic system, there are no direct pharmacogenetic interactions documented with specific drugs, including thrombolytics like alteplase or streptokinase. The gene's influence on drug behavior, including drugs used in the management of myocardial infarction and stroke, remains speculative without clinical evidence linking PLGLB1 to the pharmacokinetics or pharmacodynamics of these drugs.

**ABCG2**: ABCG2, a gene encoding an efflux transporter, significantly influences the pharmacokinetics of various drugs by altering their absorption, distribution, and excretion, impacting the effectiveness and required dosages of medications like rosuvastatin, chemotherapy agents (topotecan, methotrexate), tyrosine kinase inhibitors (sunitinib, imatinib), antiretrovirals (tenofovir), and cardiovascular drugs (atorvastatin, apixaban). Variants such as Q141K in the ABCG2 gene can further modify these drug interactions, necessitating adjustments in drug therapies to ensure optimal efficacy and safety.

**DDX39B**: DDX39B, an ATP-dependent RNA helicase, plays a significant role in mRNA processing affecting gene expression and cellular function, particularly relevant in cancer biology. While no direct pharmacokinetic interaction between DDX39B and allopurinol is evident, the suggested link might involve indirect effects through purine metabolism and RNA synthesis in rapidly proliferating cells, like leukocytes in cancers, though this connection remains speculative without specific evidence.

**PSORS1C1**: No specific pharmacokinetic interactions between PSORS1C1 and drugs have been established; however, the gene's location suggests it may indirectly influence the pharmacodynamics of drugs like carbamazepine, phenytoin, allopurinol, gemcitabine, and carboplatin. These drugs can trigger immune-mediated reactions and adverse skin reactions where PSORS1C1's role in immune response and skin integrity could be relevant.

**CYP8B1**: CYP8B1, a gene involved in bile acid synthesis, indirectly affects the pharmacokinetics of fat-soluble drugs by altering bile acid composition and thus the solubility and absorption of these medications. Although CYP8B1 does not directly interact with the metabolism of these drugs, its effect on the absorption of lipid-soluble substances, such as certain vitamins and antiepileptic drugs, can significantly influence their bioavailability, necessitating dosage adjustments in individuals with variations in this gene.

**CYP4A11**: CYP4A11, a gene involved in fatty acid metabolism, has potential pharmacogenetic implications in hypertension treatment, particularly through indirect interactions with potassium-sparing diuretics like spironolactone and amiloride. These interactions are speculated to involve modulation of hormonal pathways or ion transport mechanisms, rather than direct metabolism by the enzyme, affecting fluid and electrolyte balance critical for blood pressure regulation.

**PPP1R18**: The gene PPP1R18, which regulates the activity and specificity of protein phosphatase 1 (PP1), may influence the pharmacodynamics of cancer treatment drugs carboplatin and gemcitabine by affecting PP1's role in DNA repair and cell division control. This impact on PP1 could, thereby, modulate the effectiveness of these drugs by dictating the level of drug-induced cytotoxicity in rapidly dividing cancer cells, primarily through biochemical pathway modulation rather than changes in drug metabolism or excretion.

**RBFOX1**: Drugs used to manage epilepsy and autism spectrum disorders (ASD) may interact differently with individuals based on the RNA splicing patterns and synaptic functions regulated by the RBFOX1 gene, which plays a significant role in neurological conditions. These pharmacodynamic interactions are speculative but are based on RBFOX1's involvement in modulating neuronal communications and responses, crucial for the effectiveness of neurological medications.

**HSPA1A**: HSPA1A, a gene involved in protein folding and stress responses, does not directly interact with drugs like carbamazepine, abacavir, and flucloxacillin in altering drug concentrations in the blood. However, it may impact the efficacy and potential adverse reactions of these drugs indirectly through its role in disease-related stress responses and protein homeostasis, which are critical in conditions treated by these medications.

**CYP2C8**: The CYP2C8 gene plays a crucial role in metabolizing various medications such as paclitaxel, pioglitazone, repaglinide, and amodiaquine, affecting their efficacy and toxicity due to genetic variations that influence drug metabolism and exposure. These interactions, involving pharmacokinetic processes, suggest that CYP2C8 genetic testing could be utilized to optimize drug dosing and reduce toxicity.
